Expert Interview
A look at the Phase 1b/2 DURGA-1 study results presented at ASH evaluating AZD0120, AstraZeneca’s dual BCMA/CD19 CAR T-cell therapy for relapsed/refractory multiple myeloma
Ticker(s): AZNInstitution: Washington University St. Louis
- Professor Department of Medicine Oncology Division Bone Marrow Transplantation & Leukemia at WUSTL
- Currently treats ~300 patients with multiple myeloma, 25 patients with AML, 10 patients with CMML, and ~15 patients per month with AL Amyloidosis.
- Clinical research focus on strategies to improve the outcome of patients with multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes.
From your perspective, what differentiates AZD0120’s dual BCMA/CD19 CAR T-cell construct from currently approved single-target BCMA CAR T therapies in relapsed/refractory multiple myeloma?
Added By: sara_adminHow do you interpret the efficacy signals reported in the Phase 1b/2 DURGA-1 study, particularly in heavily pretreated or high-risk patient populations?
Added By: sara_adminDo you see dual-target CAR T approaches like AZD0120 as a meaningful strategy to address antigen escape and durability of response in multiple myeloma?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
